AIMMUNE THERAPEUTICS UK LIMITED

Aravax has appointed Louise Peacock as Chief Regulatory and Quality Officer, bringing over 35 years of pharmaceutical industry experience to the company's Oxford, UK operations.

The FDA has expanded the approval of Palforzia to include children aged 1 through 3 years with a confirmed peanut allergy.

• Nestlé Health Science has sold its peanut allergy treatment Palforzia to Stallergenes Greer, just three years after acquiring Aimmune Therapeutics for $2.6 billion. • Despite being the first FDA-approved therapy for peanut allergy in children aged 4-17, Palforzia's market performance remained modest due to complex administration requirements and clinical monitoring challenges. • The acquisition positions Stallergenes Greer as the first company to offer both respiratory and food allergy treatments, while Nestlé retains future milestone payments and royalty rights.